Loading
A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.